Amphastar Pharmaceuticals Inc (AMPH) Director Michael A. Zasloff Sells 15,000 Shares

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Director Michael A. Zasloff sold 15,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $16.52, for a total transaction of $247,800.00. Following the sale, the director now owns 29,845 shares of the company’s stock, valued at $493,039.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Amphastar Pharmaceuticals traded up $0.20, reaching $16.97, during mid-day trading on Thursday, according to Marketbeat.com. 5,028 shares of the company’s stock were exchanged, compared to its average volume of 208,308. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.40 and a quick ratio of 1.53. Amphastar Pharmaceuticals Inc has a 52-week low of $14.40 and a 52-week high of $20.45. The stock has a market cap of $773.33 million, a price-to-earnings ratio of 44.66, a price-to-earnings-growth ratio of 2.48 and a beta of 1.33.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, May 9th. The company reported ($0.05) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.08 by ($0.13). Amphastar Pharmaceuticals had a positive return on equity of 3.39% and a negative net margin of 1.50%. The business had revenue of $58.40 million for the quarter, compared to analysts’ expectations of $60.75 million. During the same period last year, the business earned $0.09 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. equities analysts expect that Amphastar Pharmaceuticals Inc will post 0.3 earnings per share for the current fiscal year.

A number of equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine upgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 15th. Wells Fargo & Co reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, March 21st. Finally, BMO Capital Markets reiterated a “market perform” rating and set a $19.00 price target (up from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $21.33.

Several institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its stake in shares of Amphastar Pharmaceuticals by 3.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,685,448 shares of the company’s stock worth $31,602,000 after purchasing an additional 53,646 shares in the last quarter. Geode Capital Management LLC grew its stake in Amphastar Pharmaceuticals by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 332,824 shares of the company’s stock worth $6,403,000 after acquiring an additional 5,435 shares during the period. Millennium Management LLC grew its stake in Amphastar Pharmaceuticals by 1,746.9% in the 4th quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock worth $5,650,000 after acquiring an additional 277,771 shares during the period. Principal Financial Group Inc. grew its stake in Amphastar Pharmaceuticals by 2.2% in the 1st quarter. Principal Financial Group Inc. now owns 273,428 shares of the company’s stock worth $5,127,000 after acquiring an additional 5,789 shares during the period. Finally, Cortina Asset Management LLC purchased a new stake in Amphastar Pharmaceuticals in the 1st quarter worth approximately $4,907,000. 44.67% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply